Implantable system for chronotherapy

Lee, Seung Ho; Wan, Qianqian; Wentworth, Adam; Ballinger, Ian; Ishida, Keiko; Collins, Joy; Tamang, Siddartha; Huang, Hen-Wei; Li, Canchen; Hess, Kaitlyn; Lopes, Aaron; Kirtane, Ameya R.; Lee, Jung Seung; Lee, SeJun; Chen, Wei; Wong, Kaitlyn E.; Selsing, George; Kim, Hyunjoon; Langer, Robert

doi:10.1126/sciadv.abj4624

Cited by 12 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[126,127] A battery-free implant that can be controlled wirelessly using a remote was developed to locally control temporal aspects of drug delivery. [128] After subcutaneous implantation, the device enables repetitive local drug delivery, and doses can easily be adapted by changing the number of actuations. [128] The system was used to deliver bromocriptine for type-2 diabetes in rats, as well as lisinopril for hypertension.…”

Section: Microchip -Implantmentioning

confidence: 99%

“…[ 128 ] After subcutaneous implantation, the device enables repetitive local drug delivery, and doses can easily be adapted by changing the number of actuations. [ 128 ] The system was used to deliver bromocriptine for type‐2 diabetes in rats, as well as lisinopril for hypertension. [ 128 ] In a first‐in‐human clinical trial, an implantable microchip‐based DDS was used to deliver human parathyroid hormone (hPTH) to eight post‐menopausal women with osteoporosis.…”

Section: Local Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Transformative Materials for Interfacial Drug Delivery

Desai

Dasgupta

Sofias

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Drug delivery systems (DDS) are designed to temporally and spatially control drug availability and activity. They assist in improving the balance between on‐target therapeutic efficacy and off‐target toxic side effects. DDS aid in overcoming biological barriers encountered by drug molecules upon applying them via various routes of administration. They are furthermore increasingly explored for modulating the interface between implanted (bio)medical materials and host tissue. Herein, an overview of the biological barriers and host‐material interfaces encountered by DDS upon oral, intravenous, and local administration is provided, and material engineering advances at different time and space scales to exemplify how current and future DDS can contribute to improved disease treatment are highlighted.

show abstract

Section: Microchip -Implantmentioning

confidence: 99%

Section: Local Deliverymentioning

confidence: 99%

Transformative Materials for Interfacial Drug Delivery

Desai

Dasgupta

Sofias

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Therefore, patients are not required to rely on continuous and repeated oral intake of medication, which will improve patient compliance [ 7 ]. A wide variety of implantable drug delivery systems have been described, including subcutaneous implants [ 10 , 11 , 12 , 13 , 14 ], cardiovascular devices [ 15 , 16 , 17 , 18 , 19 , 20 , 21 ], or orthopaedic implants [ 22 , 23 ]. Among these type of implantable devices, intranasal implants have been described for local drug delivery [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

Radiolabeled Risperidone microSPECT/CT Imaging for Intranasal Implant Studies Development

et al. 2023

View full text Add to dashboard Cite

The use of intranasal implantable drug delivery systems has many potential advantages for the treatment of different diseases, as they can provide sustained drug delivery, improving patient compliance. We describe a novel proof-of-concept methodological study using intranasal implants with radiolabeled risperidone (RISP) as a model molecule. This novel approach could provide very valuable data for the design and optimization of intranasal implants for sustained drug delivery. RISP was radiolabeled with 125I by solid supported direct halogen electrophilic substitution and added to a poly(lactide-co-glycolide) (PLGA; 75/25 D,L-Lactide/glycolide ratio) solution that was casted on top of 3D-printed silicone molds adapted for intranasal administration to laboratory animals. Implants were intranasally administered to rats, and radiolabeled RISP release followed for 4 weeks by in vivo non-invasive quantitative microSPECT/CT imaging. Percentage release data were compared with in vitro ones using radiolabeled implants containing either 125I-RISP or [125I]INa and also by HPLC measurement of drug release. Implants remained in the nasal cavity for up to a month and were slowly and steadily dissolved. All methods showed a fast release of the lipophilic drug in the first days with a steadier increase to reach a plateau after approximately 5 days. The release of [125I]I− took place at a much slower rate. We herein demonstrate the feasibility of this experimental approach to obtain high-resolution, non-invasive quantitative images of the release of the radiolabeled drug, providing valuable information for improved pharmaceutical development of intranasal implants.

show abstract

“…Automated drug delivery systems are revolutionizing the way that drugs are administrated for long-term care [1], [2] and emergency medicine [3], [4]. On-demand, pulsatile, and long-term continuous drug delivery can all be easily implemented by an electrical pump system [5].…”

Section: Introductionmentioning

confidence: 99%

Power Optimization in Battery-Powered Micro-Motors

Huang¹,

Khandelwal²,

Kerssemakers³

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

<p>Recent advances in integrated circuits and micromachining have enabled the integration of battery-powered micro-actuators in miniaturized drug delivery systems. However, the power/energy management system that treats current overloading remains sub-optimal. Overloading not only deteriorates the actuators’ long-term performance but also attenuates battery capacity. In this work, we are proposing a simple yet powerful solution to manage current overloading to maximize battery-powered system life-time. The proposed solution consists of a digitally programmable soft starter and DC-DC converter that can dynamically balance the trade-off between inrush current amplitude and motor starting speed as well as maximally minimize the continuous current draw from a battery. Our experimental results show that the proposed soft starter alone can enhance the battery capacity by 18% and together with the DC-DC converter, they can increase the drug delivery cycles by 33% without sacrificing the system’s output performance.</p>

show abstract

Implantable system for chronotherapy

Abstract: A mobile app–controlled implantable system enables chronotherapy by controlling the timing of drug administration.

Cited by 12 publications

References 42 publications

Transformative Materials for Interfacial Drug Delivery

Transformative Materials for Interfacial Drug Delivery

Radiolabeled Risperidone microSPECT/CT Imaging for Intranasal Implant Studies Development

Power Optimization in Battery-Powered Micro-Motors

Contact Info

Product

Resources

About